{"id":16201,"date":"2024-04-25T10:35:35","date_gmt":"2024-04-25T08:35:35","guid":{"rendered":"https:\/\/www.bm-t.de\/2023-en\/tvm-capital-healthcare-investiert-16-millionen-eur-in-neurocare\/"},"modified":"2024-04-25T10:47:05","modified_gmt":"2024-04-25T08:47:05","slug":"tvm-capital-healthcare-investiert-16-millionen-eur-in-neurocare","status":"publish","type":"post","link":"https:\/\/www.bm-t.de\/en\/2024-en\/tvm-capital-healthcare-investiert-16-millionen-eur-in-neurocare\/","title":{"rendered":"TVM Capital Healthcare Announces EUR 16 Million Investment into neurocare"},"content":{"rendered":"

neu\u00adro\u00adcare is rev\u00ado\u00adlu\u00adtion\u00adiz\u00ading men\u00adtal health care by pro\u00advid\u00ading inno\u00adv\u00ada\u00adtive meth\u00adods and tools based on neu\u00adrostim\u00adu\u00adla\u00adtion and other tech\u00adnolo\u00adgies to help clin\u00adi\u00adcians deliver per\u00adson\u00adal\u00adized treat\u00adments with sus\u00adtain\u00adable clin\u00adi\u00adcal out\u00adcomes for patients. The invest\u00adment will enable the com\u00adpany to exe\u00adcute on its growth plans, includ\u00ading expan\u00adsion into the MENA region.<\/em><\/p>\n

TVM Cap\u00adi\u00adtal Health\u00adcare, a spe\u00adcial\u00adist health\u00adcare pri\u00advate equity firm head\u00adquar\u00adtered in Dubai and Sin\u00adga\u00adpore, today announced a EUR 16 mil\u00adlion invest\u00adment into Munich-head\u00adquar\u00adtered neu\u00adro\u00adcare group AG (neu\u00adro\u00adcare), a lead\u00ading inno\u00adva\u00adtor in per\u00adson\u00adal\u00adized men\u00adtal health care, pro\u00advid\u00ading solu\u00adtions to empower clin\u00adi\u00adcians to deliver best care to their patients. TVM Cap\u00adi\u00adtal Health\u00adcare\u2019s invest\u00adment will enable neu\u00adro\u00adcare to exe\u00adcute on its inter\u00adna\u00adtional growth plans, includ\u00ading expan\u00adsion in the US and mar\u00adket entry into the King\u00addom of Saudi Ara\u00adbia, as well as sup\u00adport the devel\u00adop\u00adment of new hard\u00adware and soft\u00adware inno\u00adva\u00adtions. It is the ninth invest\u00adment of TVM Cap\u00adi\u00adtal Health\u00adcare to improve local access to qual\u00adity health\u00adcare in the MENA region.<\/p>\n

neu\u00adro\u00adcare, through its dig\u00adi\u00adtal ther\u00adapy plat\u00adform (DTP), pro\u00advides a holis\u00adtic and patient cen\u00adtric treat\u00adment for a vari\u00adety of psy\u00adcho\u00adlog\u00adi\u00adcal or neu\u00adro\u00adlog\u00adi\u00adcal con\u00addi\u00adtions. It uses inno\u00adv\u00ada\u00adtive men\u00adtal health care meth\u00adods and tools includ\u00ading sleep assess\u00adment, ther\u00ada\u00adpeu\u00adtics, psy\u00adchother\u00adapy, TMS and neu\u00adro\u00adfeed\u00adback, all super\u00advised within a cloud-based solu\u00adtion, to empower clin\u00adi\u00adcians and deliver indi\u00advid\u00adu\u00adal\u00adized care. Fol\u00adlow\u00ading a detailed assess\u00adment of the patien\u00adt\u2019s con\u00addi\u00adtion, neu\u00adro\u00adcare sup\u00adports clin\u00adi\u00adcians in devel\u00adop\u00ading indi\u00advid\u00adu\u00adal\u00adized ther\u00adapy plans that are designed to lead to strong, sus\u00adtain\u00adable clin\u00adi\u00adcal out\u00adcomes. neurocare\u2019s offer\u00ading is used in the Company\u2019s own clin\u00adics in the US, Europe and Aus\u00adtralia, as well as in a grow\u00ading num\u00adber of third-party clin\u00adics globally.<\/p>\n

Glob\u00adally, 12.9% of peo\u00adple are affected by men\u00adtal dis\u00ador\u00adders (WHO), caus\u00ading tremen\u00addous direct and indi\u00adrect costs, expected to increase from $2.5 tril\u00adlion in 2010 to $6 tril\u00adlion by 2030. The num\u00adber of patients diag\u00adnosed with men\u00adtal ill\u00adnesses dou\u00adbled dur\u00ading the COVID pan\u00addemic. The treat\u00adment of men\u00adtal health con\u00addi\u00adtions remains nev\u00ader\u00adthe\u00adless sig\u00adnif\u00adi\u00adcantly lack\u00ading in most coun\u00adtries, leav\u00ading a con\u00adsid\u00ader\u00adable por\u00adtion of the pop\u00adu\u00adla\u00adtion with\u00adout the nec\u00ades\u00adsary sup\u00adport, and pre\u00adsent\u00ading a unique growth oppor\u00adtu\u00adnity for com\u00adpa\u00adnies like neu\u00adro\u00adcare offer\u00ading inno\u00adv\u00ada\u00adtive non-inva\u00adsive treat\u00adments with supe\u00adrior clin\u00adi\u00adcal outcomes.<\/p>\n

Tris\u00adtan de Boys\u00adson, Man\u00adag\u00ading Part\u00adner, TVM Cap\u00adi\u00adtal Health\u00adcare, stated: \u201cThis invest\u00adment is part of our strat\u00adegy of invest\u00ading in highly inno\u00adv\u00ada\u00adtive, best-in-class health\u00adcare solu\u00adtions that improve access to qual\u00adity care across the globe. A spe\u00adcial objec\u00adtive of the Firm is improv\u00ading the health\u00adcare infra\u00adstruc\u00adture in Saudi Ara\u00adbia and the wider MENA Region. Most men\u00adtal health clin\u00adics in this region rely on tra\u00addi\u00adtional behav\u00adioural and drug care ther\u00adapy meth\u00adods, thus cre\u00adat\u00ading a first mover advan\u00adtage for com\u00adpa\u00adnies like neu\u00adro\u00adcare, offer\u00ading inno\u00adv\u00ada\u00adtive men\u00adtal health treat\u00adments with supe\u00adrior clin\u00adi\u00adcal out\u00adcomes. We are excited about bring\u00ading this offer\u00ading to the peo\u00adple in the MENA Region and are look\u00ading for\u00adward to work\u00ading together with the neu\u00adro\u00adcare man\u00adage\u00adment team to real\u00adize this objective.\u201d<\/p>\n

Thomas Mechter\u00adsheimer, Founder and CEO of neu\u00adro\u00adcare group, added: \u201cWe are very pleased to announce the coop\u00ader\u00ada\u00adtion with TVM Cap\u00adi\u00adtal Health\u00adcare, a strong part\u00adner with deep indus\u00adtry expe\u00adri\u00adence. This part\u00adner\u00adship allows us to accel\u00ader\u00adate neurocare\u2019s growth in our key mar\u00adkets in the US, Europe and Aus\u00adtralia and expand our geo\u00adgraphic foot\u00adprint into new regions. The imple\u00admen\u00adta\u00adtion of our Dig\u00adi\u00adtal Ther\u00adapy Plat\u00adform into clin\u00adics in the MENA region rep\u00adre\u00adsents a new mile\u00adstone in our com\u00adpa\u00adny\u2019s growth. I want to thank all involved par\u00adties, espe\u00adcially bm\u2011t<\/a>, Aes\u00adcu\u00advest<\/a> and Goerg Lawyers<\/a>, for their advice and sup\u00adport in clos\u00ading this financing.\u201d<\/p>\n

About TVM Capital Healthcare<\/h4>\n

TVM Cap\u00adi\u00adtal Health\u00adcare is an emerg\u00ading mar\u00adkets-focused health\u00adcare pri\u00advate equity firm head\u00adquar\u00adtered in Dubai and Sin\u00adga\u00adpore, with offices in Riyadh, and Ho Chi Minh City. The Firm invests expan\u00adsion and growth cap\u00adi\u00adtal in health\u00adcare com\u00adpa\u00adnies to improve local access to qual\u00adity care. Invest\u00adment and oper\u00adat\u00ading part\u00adners as well as a strong group of senior advi\u00adsors have long-stand\u00ading inter\u00adna\u00adtional track records in health\u00adcare invest\u00ading, active board work, con\u00adtri\u00adbu\u00adtions to strat\u00adegy devel\u00adop\u00adment and imple\u00admen\u00adta\u00adtion, and deep health\u00adcare oper\u00ada\u00adtions expe\u00adri\u00adence. The Firm part\u00adners with local Mid\u00addle East\u00adern and South\u00adeast Asian man\u00adage\u00adment teams to build domes\u00adtic or regional sec\u00adtor cham\u00adpi\u00adons and selec\u00adtively back com\u00adpa\u00adnies from Europe or North Amer\u00adica for expan\u00adsion into the Firm\u2019s two key tar\u00adget geo\u00adgra\u00adphies. TVM Cap\u00adi\u00adtal Healthcare\u2019s invest\u00adment and oper\u00adat\u00ading approach com\u00adbines strong com\u00admer\u00adcial value cre\u00adation and returns with impact and respon\u00adsi\u00adble (ESG) investing.<\/p>\n

www.tvmcapitalhealthcare.com<\/a><\/p>\n

About neurocare group AG<\/h4>\n

neu\u00adro\u00adcare is trans\u00adform\u00ading men\u00adtal health care by bring\u00ading a much-needed approach to the field: an inte\u00adgrated, per\u00adson\u00adal\u00adized treat\u00adment based on strong clin\u00adi\u00adcal evi\u00addence. neurocare\u2019s dig\u00adi\u00adtal ther\u00adapy plat\u00adform (DTP) is the first of its kind in the area of men\u00adtal health and is empow\u00ader\u00ading doc\u00adtors to offer their patients the best care for a vari\u00adety of psy\u00adcho\u00adlog\u00adi\u00adcal or neu\u00adro\u00adlog\u00adi\u00adcal con\u00addi\u00adtions. Fol\u00adlow\u00ading a detailed assess\u00adment of the patien\u00adt\u2019s con\u00addi\u00adtion, neu\u00adro\u00adcare sup\u00adports clin\u00adi\u00adcians in devel\u00adop\u00ading indi\u00advid\u00adu\u00adal\u00adized ther\u00adapy plans that are designed to lead to strong, sus\u00adtain\u00adable out\u00adcomes for patients, improv\u00ading their self-reg\u00adu\u00adla\u00adtion, resilience and social skills, while being cost effec\u00adtive for the health\u00adcare sys\u00adtem. These ther\u00adapy plans inte\u00adgrate inno\u00adv\u00ada\u00adtive meth\u00adods and tools, such as psy\u00adchother\u00adapy, neu\u00adro\u00admod\u00adu\u00adla\u00adtion and sleep hygiene, as well as med\u00adica\u00adtion, to best help each indi\u00advid\u00adual patient. This inclu\u00adsive approach uti\u00adliz\u00ading the DTP is strongly sup\u00adported by data pub\u00adlished in lead\u00ading sci\u00aden\u00adtific jour\u00adnals which showed response rates of ~65% and >55% remis\u00adsion, with very few side effects. neurocare\u2019s DTP is cur\u00adrently used in the company\u2019s clin\u00adics across the US, the Nether\u00adlands and Aus\u00adtralia, as well as in a grow\u00ading num\u00adber of third-party clinics.<\/p>\n

www.neurocaregroup.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

TVM Cap\u00adi\u00adtal Health\u00adcare Announces EUR 16 Mil\u00adlion Invest\u00adment into neurocare<\/p>\n","protected":false},"author":2,"featured_media":16198,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[248],"tags":[176,177,210,159,171],"class_list":["post-16201","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-2024-en","tag-bm-t-en","tag-bmt-en","tag-investeepartner","tag-investment-en","tag-thuringia"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/posts\/16201","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/comments?post=16201"}],"version-history":[{"count":0,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/posts\/16201\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/media\/16198"}],"wp:attachment":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/media?parent=16201"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/categories?post=16201"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/tags?post=16201"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}